Myotonic dystrophy type 1 (DM1) is the most common form of adult-onset muscular dystrophy, affecting about 1 in 8,000 people.

This announcement follows a bipartisan letter that Senator Collins and a group of nine members of Congress sent last month to ...

In November 2025, Epicrispr Biotechnologies Inc. announced a clinical trial is to learn how safe and tolerable EPI-321 is and ...

Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic ...

Adult skeletal muscle is a tissue with a high capacity for regeneration due to the existence of stem cell population, termed ...

For more than two decades, researchers at the University of Basel, Switzerland, have been investigating a severe form of muscular dystrophy in which muscles progressively degenerate. The research team ...

Webinar to be held Wednesday, December 17, 2025, at 1:00 p.m. ET –SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc.

The Muscular Dystrophy Association (MDA) today announced more than $2.7 million in new research grants to advance groundbreaking discoveries across multiple neuromuscular diseases, including ...

Myotonic dystrophy type 1 (DM1) is the most common form of adult-onset muscular dystrophy, affecting about 1 in 8,000 people.

Muscular dystrophy is a set of genetic diseases that cause muscles to become progressively weaker. Many forms of the disease ...

Many people stop taking cholesterol-lowering statins because they experience muscle aches, weakness, and fatigue.

Call it muscle dysmorphia or bigorexia, but body image issues aren’t always just about getting smaller. Experts explain why ...